Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Article

Inhibitory Effects of Leptin on Pancreatic α-Cell Function

  1. Eva Tudurí1,2,
  2. Laura Marroquí1,2,
  3. Sergi Soriano1,2,
  4. Ana B. Ropero1,2,
  5. Thiago M. Batista3,
  6. Sandra Piquer2,4,
  7. Miguel A. López-Boado5,
  8. Everardo M. Carneiro3,
  9. Ramón Gomis2,4,
  10. Angel Nadal1,2 and
  11. Ivan Quesada1,2
  1. 1Instituto de Bioingeniería, Universidad Miguel Hernandez, Elche, Spain;
  2. 2CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Barcelona, Spain;
  3. 3Instituto Nacional de Pesquisa em Obesidade e Diabetes, Departmento de Anatomia, Biologia Celulare Fisiologia, Institute of Biology, Unicamp, Campinas, Brazil;
  4. 4Endocrinology and Diabetes Unit, Laboratory of Diabetes and Obesity, IDIBAPS-Fundació Clínic, Hospital Clínic, Barcelona, Spain;
  5. 5Institut de Malalties Digestives i Metabòliques, Hospital Clínic, Barcelona, Spain.
  1. Corresponding author: Ivan Quesada, ivanq{at}umh.es.
  1. E.T. and L.M. contributed equally to this work.

Diabetes 2009 Jul; 58(7): 1616-1624. https://doi.org/10.2337/db08-1787
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • FIG. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Expression of leptin receptors in the pancreatic α-cell. A: PCR analysis of ObR transcripts shows that multiple isoforms are expressed in αTC1-9 cells. The expression in the mouse hypothalamus (Hyp) and islets is also illustrated. B: The presence of ObRb was demonstrated in αTC1-9 cells and in mouse islets by Western blot as well. An antibody that recognizes the extracellular domain of all the isoforms was also tested (ObR). Two examples are shown for the αTC1-9 cells. C and D: The spatial localization of ObRb in αTC1-9 cells and in α-cells within mouse and human islets (green) was assayed by immunofluorecence and confocal microscopy. Glucagon staining is shown in red. As in B, we also used an antibody that recognizes all the isoforms (ObR). These results are representative of at least three different experiments for each condition. Scale bar: 20 μm. (A high-quality representation of this figure is available in the online issue.)

  • FIG. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Leptin induces membrane hyperpolarization and inhibition of electrical activity. A: Recording of membrane potential in whole-cell configuration in αTC1-9 cells. With 0.5 mmol/l glucose, characteristic action potentials originated from a membrane potential of −39.9 ± 0.2 mV (n = 8). The application of leptin (6.25 nmol/l) induced hyperpolarization (21.1 ± 1.1 mV) and suppression of electrical activity. Removal of leptin allowed for a depolarization and recovery of electrical activity. Lept, leptin. B: Expanded records from A of different significant instants (indicated by numbers). C: With 0.5 mmol/l glucose, an intense electrical activity was recorded in mouse α-cells. Leptin (6.25 nmol/l) hyperpolarized these cells from −37.3 ± 0.6 mV to −60.6 ± 0.4 mV (n = 3) and decreased electrical activity. Lept, leptin. D: Expanded records from C of different significant instants (indicated by numbers).

  • FIG. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Leptin inhibits Ca2+ signals induced by low glucose concentrations in αTC1-9 cells and mouse α-cells. Leptin (6.25 nmol/l) blocks or reduces the frequency of Ca2+ signals induced with 0.5 mmol/l glucose in αTC1-9 cells (A) and α-cells (B) (n = 13 and 16, respectively). Images show a culture of αTC1-9 cells (A) and an intact mouse islet (B) loaded with the Ca2+-sensitive probe Fluo-4. Islet images were acquired by confocal microscopy from an optical section close to the equatorial plane. Several individual cells were easily identified at the periphery of the islet (white arrows). C: Average frequency of Ca2+ oscillations with 0.5 mmol/l glucose (control) and in the presence of leptin. D: Effect of 0.625 nmol/l leptin in islet α-cells (n = 20; n = 52 for αTC1-9 cells, not shown). E: Frequency (%) of Ca2+ signals after stimuli compared with control conditions. F: Leptin inhibits Ca2+ signaling in isolated islet α-cells (n = 11). The effect of adrenaline, which is characteristic of this islet cell type (32), is also shown. Data in C and E are shown as means ± SE. *Statistically significant (P < 0.05) compared with control. Adren, adrenaline; G, glucose; Lept, leptin. Scale bar: 20 μm. (A high-quality representation of this figure is available in the online issue.)

  • FIG. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Leptin decreases Ca2+ signaling in human α-cells. The application of 6.25 nmol/l leptin (A) or 0.625 nmol/l (B and C) blocks or reduces the frequency of Ca2+ signals induced with 0.5 mmol/l glucose in human α-cells. D: Average frequency of Ca2+ oscillations in 0.5 mmol/l glucose (control) and in the presence of leptin at 6.25 and 0.625 nmol/l (n = 12 and 45, respectively). Data are shown as means ± SE. Statistically significant: *P < 0.05; **P < 0.01 vs. controls. G, glucose; Lept, leptin.

  • FIG. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Leptin does not affect Ca2+ signals in the presence of wortmannin. A: In the presence of the PI3K inhibitor wortmannin (20 nmol/l), leptin was unable to affect the intracellular Ca2+ oscillations induced with 0.5 mmol/l glucose in αTC1-9 cells (n = 8). B: Average frequency of Ca2+ signals with 0.5 mmol/l glucose (control) and leptin, both in the presence of wortmannin. Data in B and C are shown as means ± SE. G, glucose; Lept, leptin; ns, nonsignificant.

  • FIG. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Effect of leptin on glucagon secretion. A: Glucagon secretion from mouse islets with 10 mmol/l glucose or with 0.5 mmol/l glucose plus 0.625 nmol/l or 6.25 nmol/l leptin was compared with the control (0.5 mmol/l glucose). The effect of wortmannin (50 nmol/l) on glucagon release with 0.5 mmol/l glucose in the absence and presence of 6.25 nmol/l leptin is also displayed. Data are shown as means ± SE (n = 8–13). B: Changes in FM1-43 fluorescence (ΔF; arbitrary units) versus time in αTC1-9 cells in control conditions (0.5 mmol/l glucose) and in the presence of leptin (6.25 nmol/l). Inset: images illustrating a group of cells in transmitted light (A) and loaded with FM1-43 at the beginning (B) and at the end of the record (C). Scale bar: 10 μm. C: The average rate of fluorescence changes as a function of time (ΔF/min) indicates that leptin reduces the exocytotic response. This effect was counteracted by wortmannin (20 nmol/l). Data are shown as means ± SE (n = 32–45 for each condition). *P < 0.05; ***P < 0.001 vs. control. G, glucose; Lept, leptin. (A high-quality representation of this figure is available in the online issue.)

Tables

  • Figures
  • TABLE 1

    PCR primers for ObR isoforms and 18S

    NameSense primer (5′-3′)Antisense primer (5′-3′)
    ObRaAGGGCTGTATGTCATTGTACCCATAGTTTAGGTTTGTTTCCCTCCATC
    ObRbACAGTTCTGGCTGTCAATTCCCAGGAGCTGCTAGAAAGACTG
    ObRcACAGTTCTGGCTGTCAATTCCCGAAAGGATGAACAGGCTTGAGAAC
    ObRdAGGGCTGTATGTCATTGTACCCATCTTCATGTAAAGATATATCCTTTTCC
    ObReAGGGCTGTATGTCATTGTACCCATCCATGAAAAGTACAGTACACATACC
    18SGGGAGGTAGTGACGAAAAATAACAATCATGGCCTCAGTTCCGAAA
PreviousNext
Back to top

In this Issue

July 2009, 58(7)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Inhibitory Effects of Leptin on Pancreatic α-Cell Function
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Inhibitory Effects of Leptin on Pancreatic α-Cell Function
Eva Tudurí, Laura Marroquí, Sergi Soriano, Ana B. Ropero, Thiago M. Batista, Sandra Piquer, Miguel A. López-Boado, Everardo M. Carneiro, Ramón Gomis, Angel Nadal, Ivan Quesada
Diabetes Jul 2009, 58 (7) 1616-1624; DOI: 10.2337/db08-1787

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Inhibitory Effects of Leptin on Pancreatic α-Cell Function
Eva Tudurí, Laura Marroquí, Sergi Soriano, Ana B. Ropero, Thiago M. Batista, Sandra Piquer, Miguel A. López-Boado, Everardo M. Carneiro, Ramón Gomis, Angel Nadal, Ivan Quesada
Diabetes Jul 2009, 58 (7) 1616-1624; DOI: 10.2337/db08-1787
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Article

  • An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes
  • Loss of Prohibitin Induces Mitochondrial Damages Altering β-Cell Function and Survival and Is Responsible for Gradual Diabetes Development
  • Cbl-b Is a Critical Regulator of Macrophage Activation Associated With Obesity-Induced Insulin Resistance in Mice
Show more Original Article

Islet Studies

  • Cell Cycle Regulation of the Pdx1 Transcription Factor in Developing Pancreas and Insulin-Producing β-Cells
  • Dynamic Uni- and Multicellular Patterns Encode Biphasic Activity in Pancreatic Islets
  • Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing β-Cell Mass in db/db Mice
Show more Islet Studies

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.